FI950887A0 - MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt - Google Patents

MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt

Info

Publication number
FI950887A0
FI950887A0 FI950887A FI950887A FI950887A0 FI 950887 A0 FI950887 A0 FI 950887A0 FI 950887 A FI950887 A FI 950887A FI 950887 A FI950887 A FI 950887A FI 950887 A0 FI950887 A0 FI 950887A0
Authority
FI
Finland
Prior art keywords
hla
presented
mage
gene
derived
Prior art date
Application number
FI950887A
Other languages
English (en)
Swedish (sv)
Other versions
FI950887A (fi
Inventor
Thierry Boon-Falleur
Der Bruggen Pierre Van
Plaen Etienne De
Christophe Lurquin
Catia Traversari
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,334 external-priority patent/US5405940A/en
Priority claimed from US08/037,230 external-priority patent/US6235525B1/en
Priority claimed from US08/073,103 external-priority patent/US5462871A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI950887A0 publication Critical patent/FI950887A0/fi
Publication of FI950887A publication Critical patent/FI950887A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
FI950887A 1992-08-31 1995-02-27 MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt FI950887A (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/938,334 US5405940A (en) 1992-08-31 1992-08-31 Isolated nonapeptides derived from MAGE genes and uses thereof
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US08/073,103 US5462871A (en) 1992-08-31 1993-06-07 Isolated nucleic acid molecules which encode MAGE derived nonapeptides
PCT/US1993/008157 WO1994005304A1 (en) 1992-08-31 1993-08-30 Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof

Publications (2)

Publication Number Publication Date
FI950887A0 true FI950887A0 (fi) 1995-02-27
FI950887A FI950887A (fi) 1995-02-27

Family

ID=26713936

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950887A FI950887A (fi) 1992-08-31 1995-02-27 MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt

Country Status (12)

Country Link
US (2) US6379901B1 (fi)
EP (1) EP0658113B1 (fi)
JP (1) JP3608788B2 (fi)
AT (2) ATE280180T1 (fi)
AU (1) AU668772B2 (fi)
CA (1) CA2143335C (fi)
DE (1) DE69333670T2 (fi)
DK (1) DK0658113T3 (fi)
ES (1) ES2225824T3 (fi)
FI (1) FI950887A (fi)
PT (1) PT658113E (fi)
WO (1) WO1994005304A1 (fi)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US6222012B1 (en) * 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
WO1996029409A2 (en) * 1995-03-21 1996-09-26 Ludwig Institute For Cancer Research Rage tumor rejection antigens
EP0873350A4 (en) * 1995-06-29 1999-06-30 Ludwig Inst Cancer Res ISOLATION OF A NUCLEIC ACID MOLECULE ENCODING SMAGE-3, A MURINE TUMOR REJECTION ANTIGEN PRECURSOR
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
ATE505542T1 (de) 1998-02-05 2011-04-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US7083789B2 (en) 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002306600A1 (en) * 2001-02-26 2002-09-12 Albany Medical College Sperm protein 17 for the diagnosis and treatment of cancer
AU2002244862B2 (en) 2001-04-12 2007-09-20 Imperial Innovations Limited Diagnosis and treatment of cancer: I
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren
CA2510238A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
ES2661082T3 (es) 2003-01-30 2018-03-27 Survac Aps Péptidos derivados de survivina y uso de los mismos
PL2087904T3 (pl) 2003-11-19 2014-01-31 Survac Aps Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
RU2012139182A (ru) 2010-02-22 2014-03-27 Ф. Хоффманн-Ля Рош Аг ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
WO2013039889A1 (en) * 2011-09-15 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
CA3002954A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
SI3565828T1 (sl) 2017-01-05 2022-04-29 Kahr Medical Ltd. SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2019006003A1 (en) 2017-06-27 2019-01-03 The Trustees Of Princeton University COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
EP3743093A1 (en) 2018-01-26 2020-12-02 Cambridge Enterprise Limited Peptide exchange protein
MX2021000263A (es) 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020041662A1 (en) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
KR20220044284A (ko) 2019-07-11 2022-04-07 카 메디컬 리미티드 이종이량체 및 이의 사용방법
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492760A (en) * 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
EP0398962A1 (en) * 1988-02-05 1990-11-28 Genzyme Corporation Rearranged tissue plasminogen activators and method for producing same
AU8305491A (en) 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
NZ255683A (en) * 1992-08-07 1996-08-27 Cytel Corp Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
ATE378406T1 (de) 2007-11-15
WO1994005304A1 (en) 1994-03-17
EP0658113A4 (en) 1997-11-26
DE69333670D1 (de) 2004-11-25
PT658113E (pt) 2005-03-31
ES2225824T3 (es) 2005-03-16
AU668772B2 (en) 1996-05-16
JP3608788B2 (ja) 2005-01-12
DK0658113T3 (da) 2005-02-14
FI950887A (fi) 1995-02-27
AU5096993A (en) 1994-03-29
US5695994A (en) 1997-12-09
CA2143335A1 (en) 1994-03-17
EP0658113A1 (en) 1995-06-21
JPH08500837A (ja) 1996-01-30
ATE280180T1 (de) 2004-11-15
US6379901B1 (en) 2002-04-30
DE69333670T2 (de) 2005-03-10
EP0658113B1 (en) 2004-10-20
CA2143335C (en) 2000-03-14

Similar Documents

Publication Publication Date Title
FI950887A0 (fi) MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
NO950660L (no) Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav
ATE130029T1 (de) Hybridome, die monoklonale antikörper gegen neue mucin-epitope produzieren.
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69727966D1 (de) Ein mit krebs assoziiertes antigen kodierendes isoliertes nukleinsäuremolekül, das antigen selbst, und dessen verwendungen
ATE258379T1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
FI963780A (fi) Kasvainhyljintäantigeeniprekursorista MAGE-2 saatuja eristettyjä peptidejä ja niiden käyttöjä
ATE267254T1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
FI954536A (fi) Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö
GR1000456B (el) Μεθοδος παρασκευης φαρμακευτικων συνθεσεων που περιλαμβανουν κυκλοσπορινες.
DE69511399T2 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
ATE60574T1 (de) Hydroxylierte 1,2-diamincyclohexan platinkomplexe.
NO20020329D0 (no) Antitumor antistoffer, proteiner og anvendelser derav
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung